March 2025
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Elevation Oncology Discontinues Lead Drug and Cuts Workforce
EO-3021, Claudin 18.2 ADC, Phase 1 trial, gastric cancer, layoffs, strategic options
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Sanofi Expands Immunology Pipeline with $600M Acquisition of Dren Bio’s Novel B-Cell Depleting Bispecific Antibody
Bispecific antibody, Myeloid cell engager, B-cell depletion, Autoimmune diseases, Immunology pipeline, Phagocytosis, CD20-directed therapy
Paratek Expands into Chronic Rhinosinusitis Market with $330M Optinose Acquisition
Paratek Pharmaceuticals, Optinose , XHANCE, Chronic rhinosinusitis, Nasal drug delivery, Pharmaceutical acquisition, Specialty pharma
Purdue Pharma’s $7.4 Billion Opioid Settlement and Bankruptcy Filing
Purdue Pharma, Sackler family, opioid crisis, bankruptcy, settlement, OxyContin